Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
https://doi.org/10.17650/1818-8346-2012-7-1-29-34
Abstract
Persistent thrombocytopenia is a frequent complication after allogeneic bone marrow transplantation (BMT). The major causes of thrombocytopenia include accelerated platelet destruction by antiplatelet antibodies, microangiopathy, viral infection, drug toxicity,
graft`s hypofunction with insufficient production of platelets from megakaryocytes. We have evaluated an efficacy of TPO-receptor agonist
romiplostim in treatment of 3 patients with refractory thrombocytopenia after allogeneic BMT. The first 30 years old patient received haploidentical allogeneic stem cell transplantation for refractory AML relapse. He developed graft hypofunction due to CMV infection, acute GVHD and thrombotic thrombocytopenic purpura (TTP) with platelet counts 5 × 109/l and bleeding complications. After bone marrow “boost” the patient received romiplostim 1 mkg/kg weekly during 2 weeks and 4 mkg/kg during another 2 weeks. Upon reaching platelet counts 50 × 109/l the romiplostim was stopped, but platelet count decreased to 5–7 × 109/l and romiplostim was administered in dose of 4 mkg/kg weekly during 5 weeks. Platelet counts have achieved 150 × 109/l and thrombocytopenia during further follow-up was not revealed. The second 19 years old AML patient received haploidentical allogeneic stem cell transplantation for second remission consolidation. He developed thrombocytopenia (10 × 109/l) due to CMV infection and severe TTP. He received romiplostim 4 mkg/kg weekly and 5 weeks later platelet counts was 50 × 109/l. The administration of romiplostim was allowed to avoid bleeding complications and transfusion dependency. The third 18 years old ALL patient received MUD allogeneic stem cell transplantation for second remission consolidation. He developed profound thrombocytopenia (5 × 109/l) with severe hemorrhagic complications and platelet transfusions refractory due to TTP and acute GVHD. He received one dose of romiplostim 1 mkg/kg and two doses of 3 mkg/kg weekly with completion of hemorrhagic syndromes and achieving 20 × 109/l blood platelet counts. Romiplostim was continued in dose 5 mkg/kg/wk during 2 weeks and stable platelet counts > 30 × 109/l was achieved. The romiplostim efficacy in these patients supports the use of TPO-agonists in patients after allogeneic BMT who developed severe thrombocytopenia due to TTP, CMV infections, acute GVHD and other posttransplant complications.
About the Authors
I. A. LisukovRussian Federation
O. S. Uspenskaya
Russian Federation
A. D. Kulagin
Russian Federation
S. N. Bondarenko
Russian Federation
T. A. Rudakova
Russian Federation
O. A. Slesarchuk
Russian Federation
B. V. Afanasyev
Russian Federation
References
1. Kim D., Sohn S., Jeon S. et al. Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. Bone Marrow
2. Transplant 2006;37:101–8.
3. Bolwell B., Pohlman B., Sobecks R. et al. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant 2004;33:419–23.
4. First L., Smith B., Lipton J. et al. Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. Blood 1985;65:368–74.
5. Yamazaki R., Kuwana M., Mori T. et al. Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet
6. turnover. Bone Marrow Transplant 2006;38:377–84.
7. Hijyama K., Wada H., Shimura M. et al. Increased serum levels of thrombopoietin in patients with thrombotic thrombocytopenic purpura? Idiopathic thrombocytopenic purpura, or disseminated intravascular coagulation. Blood Coagul Fibrinolysis 1997;8(6):345–9.
8. Usui K., Tahara T., Iki S. et al. Serum thrombopoietin level in various hematological diseases. Stem Cells 1996;14(5):558–65.
9. Aledort L., Hayward C., Chen M. et al. Prospective screening of 205 patients withITP, including diagnosis, serological markers and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombpoietin antibodies. Am J Hematol 2004;76(3):205–13.
10. Keever-Taylor C., Klein J., Eastwood D. et al. Factors affecting neutrophil and platelet reconstitution following T celldepleted bone marrow transplantation: differential effects of growth factor type and role of CD34+ cell dose. Bone Marrow Transplant 2001;27:791–800.
11. Singhal S., Powles R., Treleaven J. et al. A low CD34+ cell dose results in high mortality and poorer survival after blood or marrow stem cell transplantation fromHLA-identical siblings: should 2 × 10(6)
12. CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant2000;26:489–96.
13. Verdonck L., de Gast G., van Heugten H. et al. Cytomegalovirus infection causesdelayed platelet recovery after bone marrow transplantation. Blood 1991;78:844–8.
14. Zhang X., Fu H., Xu L. et al. Prolonged thrombocytopenia following allogeneichematopoietic stem cell transplantation and ts association with a reduction in ploidy and an immaturation of megakaryocytic. Biol Blood Marrow Transplant 2011;17:274–80.
15. Wang B., Nichol J., Sullivan J. et al. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004;76:628–38.
16. Bussel J., Kuter D., George R. et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;255:1672–81.
17. Steensma D. Hematopoetic growth factors in myelodysplastic syndromes. Semin Oncol 2011;38(5):635–47.
18. Panzer S. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia. Drugs Today 2009;45(2):93–9.
19. Bussel J., Kuter D., George J. et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;335:1672–81.
20. Gangatharan S., Cooney J. Persistent thrombocytopenia post auto-SCT for AML treated with romiplostim in a patient with HIV. Bone Marrow Transplant 2011;46(9):1280–1.
21. Beck J., Burke M., Tolar J. Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim. Pediatr Blood Cancer 2010;54:490–1.
22. Rank A., Weigert O., Stermann H. Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle. Biologics: Targets &
23. Therapy 2010;4:139–45.
Review
For citations:
Lisukov I.A., Uspenskaya O.S., Kulagin A.D., Bondarenko S.N., Rudakova T.A., Slesarchuk O.A., Afanasyev B.V. Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation. Oncohematology. 2012;7(1):29-34. (In Russ.) https://doi.org/10.17650/1818-8346-2012-7-1-29-34